The level of PD-L1 expression, generally assessed by combined positive score (CPS) or tumor proportion score (TPS), stands as a prognostic biomarker for predicting the efficacy of PD-1/PD-L1 inhibitors (19, 20). This evidence concerns the gene CD274 and neoplasm.